Profile data is unavailable for this security.
About the company
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
- Revenue in DKK (TTM)0.00
- Net income in DKK-26.05m
- Incorporated2009
- Employees1.00
- LocationOrphazyme A/SOle Maaloees Vej 3, Copenhagen NKOEBENHAVN 2200DenmarkDNK
- Websitehttps://www.orphazyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veg of Lund AB (publ) | 3.10m | -12.80m | 28.65m | 7.00 | -- | 1.06 | -- | 9.25 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
| NextCell Pharma AB | 8.00m | -25.31m | 29.83m | -- | -- | 0.8312 | -- | 3.73 | -1.15 | -1.15 | 0.3621 | 1.62 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Scandion Oncology A/S | 0.00 | -39.20m | 31.01m | 4.00 | -- | 0.9965 | -- | -- | -1.51 | -1.51 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -63.25 | -45.09 | -76.67 | -52.65 | -- | -- | -- | -- | -- | -- | 0.0158 | -- | -- | -- | 48.89 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | 0.00 | -11.82m | 31.56m | 5.00 | -- | 1.19 | -- | -- | -0.1824 | -0.355 | 0.00 | 0.3862 | 0.00 | -- | -- | 0.00 | -19.03 | -37.28 | -31.28 | -51.56 | -- | -- | -- | -2,077.34 | -- | -3.88 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
| SoftOx Solutions AS | 4.50m | -27.11m | 32.69m | -- | -- | -- | -- | 7.27 | -1.98 | -1.98 | 0.3286 | -0.0127 | 0.081 | -- | 1.60 | -- | -48.81 | -50.83 | -82.20 | -64.58 | -- | -- | -602.91 | -646.67 | 0.1745 | -3.45 | -- | -- | -1.88 | 10.06 | 40.85 | -- | 39.43 | -- |
| Alzinova AB | 173.56k | -10.59m | 34.24m | 5.00 | -- | 0.4678 | -- | 197.26 | -0.418 | -0.418 | 0.0067 | 2.56 | 0.0023 | -- | 0.3671 | 54,000.00 | -14.04 | -10.77 | -14.91 | -11.27 | 7,360.92 | -- | -6,103.69 | -18,447.90 | -- | -- | 0.007 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Spago Nanomedical AB (publ) | 941.72k | -22.12m | 35.39m | 12.00 | -- | 1.61 | -- | 37.58 | -0.2454 | -0.2454 | 0.0107 | 0.1525 | 0.0324 | -- | 9.90 | 112,692.30 | -76.02 | -20.19 | -90.21 | -20.97 | 115.84 | -- | -2,349.01 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Immunovia AB (publ) | 779.09k | -167.60m | 35.40m | 11.00 | -- | 1.26 | -- | 45.44 | -6.06 | -6.06 | 0.0276 | 0.9648 | 0.0075 | 58.23 | 14.96 | 110,181.80 | -160.93 | -41.33 | -194.89 | -44.24 | -5,523.76 | -7,553.76 | -21,512.13 | -20,879.29 | 2.03 | -- | 0.1675 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| PCI Biotech Holding ASA | 1.93m | -13.09m | 36.07m | 7.00 | -- | 1.43 | -- | 18.73 | -0.5443 | -0.5443 | 0.0801 | 1.05 | 0.0556 | -- | 0.6848 | 427,142.80 | -37.78 | -36.44 | -41.97 | -40.14 | -- | -- | -679.43 | -1,055.43 | -- | -- | 0.0081 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Orphazyme A/S | 0.00 | -26.05m | 36.82m | 1.00 | -- | 2.59 | -- | -- | -737.75 | -737.75 | 0.00 | 403.34 | 0.00 | -- | -- | 0.00 | -68.42 | -76.08 | -94.18 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Pila Pharma AB | 940.45k | -6.38m | 37.01m | 1.00 | -- | 8.64 | -- | 39.36 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Combigene AB | 3.56m | -22.93m | 39.46m | 8.00 | -- | 0.5271 | -- | 11.07 | -1.80 | -1.80 | 0.28 | 5.88 | 0.0398 | -- | 2.63 | 693,015.00 | -25.58 | -13.00 | -26.56 | -14.58 | -- | -- | -643.32 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 958.29k | -10.33m | 42.21m | 10.00 | -- | 10.19 | -- | 44.05 | -0.1635 | -0.1635 | 0.0145 | 0.0638 | 0.1306 | -- | 26.83 | 149,078.00 | -140.73 | -80.90 | -200.07 | -106.45 | -389.14 | -1,073.66 | -1,078.00 | -1,360.03 | -- | -2.71 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -87.94m | 42.41m | 16.00 | -- | 0.5307 | -- | -- | -0.3953 | -0.3953 | 0.00 | 0.2488 | 0.00 | -- | -- | 0.00 | -64.42 | -- | -84.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| ExpreS2ion Biotech Holding AB | 4.99m | -50.10m | 43.29m | 18.00 | -- | 1.29 | -- | 8.67 | -1.56 | -1.56 | 0.1509 | 1.02 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| ViroGates A/S | 5.73m | -12.75m | 45.13m | 10.00 | -- | 3.36 | -- | 7.87 | -6.00 | -6.00 | 1.44 | 2.08 | 0.3344 | 0.316 | 3.64 | 573,300.00 | -74.36 | -46.58 | -80.05 | -52.09 | 77.20 | 77.91 | -222.40 | -238.01 | 10.45 | -19.08 | 0.2833 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Orphazyme A/S's reporting currency: Danish Krone DKK
0.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 29 Feb 2024 | 70.00 | 0.20% |
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
